CD19 and neoplasm: As shown in Fig. S8A–D, while tumor growth was not effectively controlled in all treatment groups, possibly due to an overwhelming initial tumor burden, the group treated with CD19-BBζ + CD2 CAR-T cells presented the lowest tumor burden and a trend toward prolonged survival.